FDA Approves AstraZeneca's ETCAMAH for Advanced Breast Cancer Treatment

Key Facts

1AstraZeneca's ETCAMAH (camizestrant) received US approval for first-line treatment of advanced HR-positive breast cancer.

In a move that strengthens AstraZeneca's position in the global oncology market, the US FDA has approved ETCAMAH (camizestrant) as a first-line treatment for advanced breast cancer. The approval covers the use of the drug in combination with CDK4/6 inhibitors for patients with hormone receptor (HR)-positive advanced disease. This regulatory milestone follows clinical data supporting the efficacy of camizestrant as a next-generation selective estrogen receptor degrader (SERD), providing a critical new therapeutic option for advanced cases.

Per market data, AstraZeneca's shares showed relative stability following the regulatory news, with AZN closing at $162.70 in New York on September 4, 2026. In London, AZN.L recorded a price of 12,006 pence at the close of the same day, with the stock trading between 11,984 and 12,208 pence during the session. These movements reflect investor response to growth prospects in the pharmaceutical sector, while updated price data was unavailable for AZNCF and ZEG.DE.

Looking ahead, traders are monitoring AZN's performance, which hit a day high of $163.78 (close September 4, 2026), as a signal of momentum following the approval. With the immediate economic calendar lacking direct pharmaceutical sector events, focus will shift toward the company's operational reports to assess the commercial rollout timeline. Immediate support levels remain near the September 4 session low of $161.13 as a technical reference for near-term investors.